Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

IAS: Antiretroviral Fusion Inhibitor T-20 Suppresses HIV for 48 Weeks By Ed Susman PARIS, FRANCE -- July 17, 2003 -- The antiretroviral fusion inhibitor T-20 appears to maintain its effectiveness in heavily pretreated patients with HIV, researchers reported here on July 16th at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. In a late-breaking presentation, David Cooper, MD, DSc, professor of medicine, University of New South Wales, and Director, National Centre in HIV Epidemiology and Clinical Research, Sydney, Australia, said patients on T-20 and their optimal background medication were able to maintain undetectable viral levels after 48 weeks of treatment. The T-20 versus Optimized Regimen Only (TORO) results showed that, after 48 weeks, 30% of the patients on T-20 had maintained undetectable viral loads, compared with 12% of those on background medication only. Results reported at 24 weeks showed that 32.7% of patients had reached undetectable viral loads, compared with 15% of those on background regimen alone. The differences, said Dr. Cooper, were statistically significant at the P<0.001 level. In addition, he noted that after 1 year, 37.2% of patients taking T-20 had achieved a greater than 90% (1-log) reduction in viral load, compared with 17.1% patients who were maintained on their background medication. After 24 weeks, the researchers reported that 47.2% of patients on T-20 had achieved a greater than 1-log reduction in viral load compared with 24.9% of patients on background medication. "T-20 appears to be more durable than some of us would have believed," said Mark Wainberg, MD, Director, McGill University AIDS Centre, Montreal, Canada. In the TORO studies, patients were randomized in an open-label fashion on a 2-to-1 basis to receive either 90 mcg T-20 by subcutaneous injection twice a day on top of the best other HIV treatment or continuing on the best available treatment. The international studies -- TORO 1 in North America and TORO 2 in Europe and Australia -- enrolled 995 patients. All of the patients in the study had been treated with numerous antiretroviral treatment. "The median number of antiretroviral drugs used was 12 among these patients," Dr. Cooper said. "They had been treated an average of 7 years with antiretrovirals." Robert Murphy, MD, clinical professor of infectious diseases, Northwestern University School of Medicine, Chicago, Illinois, said the durability of T-20 surprised researchers. " I don't see the drug being used other than as a second-line or salvage therapy, however, because of its mode of administration," he said in a press briefing. Dr. Wainberg said that an oral form of T-20 is in development, and its success could push the drug into first-line status. This study was supported by Roche Pharmaceuticals, Basel, Switzerland. [Study title: Enfuvirtide TORO Studies: 48 Week Results Confirm 24 Week Findings. Abstract LB2] E-mail this page to a friend or colleague! To print, use this version